Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Inclusion Criteria:

* Age ≥ 18 years.
* Diagnosis of Ph+ or BCR-ABL positive CML-CP within 6 months.
* ECOG performance of 0-2.
* Adequate end organ function defined as the following: total bilirubin \<1.5x ULN, SGPT \<2.5x ULN, creatinine \<1.5x ULN.
* Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital

Exclusion Criteria:

* History of any TKI treatments.
* History of Pulmonary arterial hypertension and Pleural effusion
* NYHA cardiac class 3-4 heart disease.
* Cardiac symptoms - Patients meeting the following criteria are not eligible unless cleared by a cardiologist:
* Uncontrolled angina within 12 months.
* Diagnosed or suspected congenital long QT syndrome.
* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes).
* Prolonged QTc interval on pre-entry electrocardiogram (\>450 msec).
* Patients with active uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders.
* Women of pregnancy potential must practice an effective method of birth control, unless otherwise instructed, during the course of the study in a manner such that risk of failure is minimized.
* Pregnant or breast-feeding women are excluded.
* Patients in late chronic phase (i.e. time from diagnosis to treatment \>12 months), accelerated phase (except as noted in inclusion criteria 2) or blast phase are excluded.